Michael Krel

Elicit Plant SAS is a French agri-biotech company that aims to become a leader in the ecological transition for agriculture and address the challenges posed by climate change on large-scale crops. The company is based in Moulins-sur-Tardoire, France. The company's proprietary technology, based on the exogenous application of phytosterols, enhances plant stress resistance by eliciting their natural defenses. Extensive field trials across three continents have proven that the biosolutions from the eliterra® platform are the only ones providing farmers with a regular and sufficient return on investment for use in large-scale crops, yielding an average increase in productivity of 12%%. The company was founded in 2017 by Jean-François Dechant, who has been the CEO since 2017.

EnginZyme AB is a Swedish company founded in 2014 by Samuel Härgestam, Robin Chatterjee, and Karim Engelmark Cassimjee. EnginZyme is based in Stockholm, Sweden, and has a multidisciplinary team of experts in biocatalysis, organic chemistry, enzyme and process engineering, as well as AI and machine learning. The company has developed a patented, cell-free biomanufacturing platform that combines the power of biology with the efficiencies of the chemical industry. EnginZyme aims to produce better, greener, and more affordable products sustainably. The company's enzyme immobilisation technology enables biomanufacturing without living organisms, resulting in lower costs and a smaller environmental footprint. The company has been recognized as a technology pioneer by the World Economic Forum and was selected for the Cleantech 100 list in 2022 and 2023. Karim Engelmark Cassimjee has been the CEO since 2014.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

EnginZyme AB is a Swedish company founded in 2014 by Samuel Härgestam, Robin Chatterjee, and Karim Engelmark Cassimjee. EnginZyme is based in Stockholm, Sweden, and has a multidisciplinary team of experts in biocatalysis, organic chemistry, enzyme and process engineering, as well as AI and machine learning. The company has developed a patented, cell-free biomanufacturing platform that combines the power of biology with the efficiencies of the chemical industry. EnginZyme aims to produce better, greener, and more affordable products sustainably. The company's enzyme immobilisation technology enables biomanufacturing without living organisms, resulting in lower costs and a smaller environmental footprint. The company has been recognized as a technology pioneer by the World Economic Forum and was selected for the Cleantech 100 list in 2022 and 2023. Karim Engelmark Cassimjee has been the CEO since 2014.

Elicit Plant SAS is a French agri-biotech company that aims to become a leader in the ecological transition for agriculture and address the challenges posed by climate change on large-scale crops. The company is based in Moulins-sur-Tardoire, France. The company's proprietary technology, based on the exogenous application of phytosterols, enhances plant stress resistance by eliciting their natural defenses. Extensive field trials across three continents have proven that the biosolutions from the eliterra® platform are the only ones providing farmers with a regular and sufficient return on investment for use in large-scale crops, yielding an average increase in productivity of 12%%. The company was founded in 2017 by Jean-François Dechant, who has been the CEO since 2017.

EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France.

Werewool, Inc. develops fibers. The CEO of the American company is Chui-Lian Lee.

Elicit Plant SAS is a French agri-biotech company that aims to become a leader in the ecological transition for agriculture and address the challenges posed by climate change on large-scale crops. The company is based in Moulins-sur-Tardoire, France. The company's proprietary technology, based on the exogenous application of phytosterols, enhances plant stress resistance by eliciting their natural defenses. Extensive field trials across three continents have proven that the biosolutions from the eliterra® platform are the only ones providing farmers with a regular and sufficient return on investment for use in large-scale crops, yielding an average increase in productivity of 12%%. The company was founded in 2017 by Jean-François Dechant, who has been the CEO since 2017.

Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France.

Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France.

Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

EnginZyme AB is a Swedish company founded in 2014 by Samuel Härgestam, Robin Chatterjee, and Karim Engelmark Cassimjee. EnginZyme is based in Stockholm, Sweden, and has a multidisciplinary team of experts in biocatalysis, organic chemistry, enzyme and process engineering, as well as AI and machine learning. The company has developed a patented, cell-free biomanufacturing platform that combines the power of biology with the efficiencies of the chemical industry. EnginZyme aims to produce better, greener, and more affordable products sustainably. The company's enzyme immobilisation technology enables biomanufacturing without living organisms, resulting in lower costs and a smaller environmental footprint. The company has been recognized as a technology pioneer by the World Economic Forum and was selected for the Cleantech 100 list in 2022 and 2023. Karim Engelmark Cassimjee has been the CEO since 2014.

Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada.

Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada.

Werewool, Inc. develops fibers. The CEO of the American company is Chui-Lian Lee.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada.

Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France.

EnginZyme AB is a Swedish company founded in 2014 by Samuel Härgestam, Robin Chatterjee, and Karim Engelmark Cassimjee. EnginZyme is based in Stockholm, Sweden, and has a multidisciplinary team of experts in biocatalysis, organic chemistry, enzyme and process engineering, as well as AI and machine learning. The company has developed a patented, cell-free biomanufacturing platform that combines the power of biology with the efficiencies of the chemical industry. EnginZyme aims to produce better, greener, and more affordable products sustainably. The company's enzyme immobilisation technology enables biomanufacturing without living organisms, resulting in lower costs and a smaller environmental footprint. The company has been recognized as a technology pioneer by the World Economic Forum and was selected for the Cleantech 100 list in 2022 and 2023. Karim Engelmark Cassimjee has been the CEO since 2014.

Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

Elicit Plant SAS is a French agri-biotech company that aims to become a leader in the ecological transition for agriculture and address the challenges posed by climate change on large-scale crops. The company is based in Moulins-sur-Tardoire, France. The company's proprietary technology, based on the exogenous application of phytosterols, enhances plant stress resistance by eliciting their natural defenses. Extensive field trials across three continents have proven that the biosolutions from the eliterra® platform are the only ones providing farmers with a regular and sufficient return on investment for use in large-scale crops, yielding an average increase in productivity of 12%%. The company was founded in 2017 by Jean-François Dechant, who has been the CEO since 2017.

EnginZyme AB is a Swedish company founded in 2014 by Samuel Härgestam, Robin Chatterjee, and Karim Engelmark Cassimjee. EnginZyme is based in Stockholm, Sweden, and has a multidisciplinary team of experts in biocatalysis, organic chemistry, enzyme and process engineering, as well as AI and machine learning. The company has developed a patented, cell-free biomanufacturing platform that combines the power of biology with the efficiencies of the chemical industry. EnginZyme aims to produce better, greener, and more affordable products sustainably. The company's enzyme immobilisation technology enables biomanufacturing without living organisms, resulting in lower costs and a smaller environmental footprint. The company has been recognized as a technology pioneer by the World Economic Forum and was selected for the Cleantech 100 list in 2022 and 2023. Karim Engelmark Cassimjee has been the CEO since 2014.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France.